848440-23-3

Basic information

• Product Name: Carbamic acid, (3-bromo-2-fluorophenyl)-, 1,1-dimethylethyl ester
• Synonyms: tert-butyl (3-bromo-2-fluorophenyl) carbamate;N-Boc-3-bromo-2-fluoroaniline
• CAS NO: 848440-23-3
• Molecular Formula: C11H13BrFNO2
• Molecular Weight: 290.132
• Mol File: 848440-23-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 271.2±30.0 °C(Predicted)
• Density: 1.459±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Carbamic acid, (3-bromo-2-fluorophenyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-bromo-2-fluorophenyl)-, 1,1-dimethylethyl ester(848440-23-3)
• EPA Substance Registry System: Carbamic acid, (3-bromo-2-fluorophenyl)-, 1,1-dimethylethyl ester(848440-23-3)

Safety Data

• Hazardous Substances Data: 848440-23-3(Hazardous Substances Data)

Upstream product

• 58534-95-5 3-bromo-2-fluorobenzenamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 161957-56-8 3-bromo-2-fluorobenzoic acid 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 1099766-43-4 tert-butyl [3-(4-hydroxybut-1-yn-1-yl)-2-fluorophenyl]carbamate 
• 1357587-26-8 N-[3-(1-ethyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-2-fluorophenyl]-3-fluorobenzenesulfonamide 
• 1357588-11-4 [2-fluoro-3-(2H-pyrazol-3-yl)phenyl]carbamic acid tert-butyl ester 
• 1357588-12-5 [3-(4-bromo-2H-pyrazol-3-yl)-2-fluorophenyl]carbamic acid tert-butyl ester 
• 1357588-14-7 [3-(1-ethyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-2-fluorophenyl]carbamic acid tert-butyl ester 
• 1357588-15-8 3-(1-ethyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-2-fluorophenylamine 
• 1357588-10-3 {2-fluoro-3-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]phenyl}carbamic acid tert-butyl ester 
• 449758-17-2 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole 
• 58534-95-5 3-bromo-2-fluorobenzenamine 
• 1188227-29-3 7-bromo-2-chlorobenzothiazole 

Relevant articles and documents

DIACYLGLYCEROL KINASE MODULATING COMPOUNDS

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS

The invention relates to N-(substituted-phenyl)-sulfonamide compounds, which are extremely useful as inhibitors of protein kinases (e.g. PERK kinase) and accordingly can be used for the treatment of cell proliferative disorders, such as cancer, or diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Small molecules enhance functional O-mannosylation of Alpha-dystroglycan

Alpha-dystroglycan (α-DG), a highly glycosylated receptor for extracellular matrix proteins, plays a critical role in many biological processes. Hypoglycosylation of α-DG results in various types of muscular dystrophies and is also highly associated with progression of majority of cancers. Currently, there are no effective treatments for those devastating diseases. Enhancing functional O-mannosyl glycans (FOG) of α-DG on the cell surfaces is a potential approach to address this unmet challenge. Based on the hypothesis that the cells can up-regulate FOG of α-DG in response to certain chemical stimuli, we developed a cell-based high-throughput screening (HTS) platform for searching chemical enhancers of FOG of α-DG from a large chemical library with 364,168 compounds. Sequential validation of the hits from a primary screening campaign and chemical works led to identification of a cluster of compounds that positively modulate FOG of α-DG on various cell surfaces including patient-derived myoblasts. These compounds enhance FOG of α-DG by almost ten folds, which provide us powerful tools for O-mannosylation studies and potential starting points for the development of drug to treat dystroglycanopathy.